Overview

This trial is active, not recruiting.

Condition acne
Treatment cd0271/cd1579, vehicle
Phase phase 1
Sponsor Galderma R&D
Start date August 2012
End date September 2013
Trial size 38 participants
Trial identifier NCT01688531, NCT01718665, RD.03.SPR.40183E

Summary

Exploratory, international, multi-centre, randomized, investigator blinded study in acne

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking single blind (investigator)
Primary purpose basic science
Arm
(Experimental)
cd0271/cd1579, vehicle

Primary Outcomes

Measure
Description and documentation of acne lesions
time frame: over 6 months

Secondary Outcomes

Measure
Treatment effect on acne lesions
time frame: over 6 months

Eligibility Criteria

Male or female participants from 18 years up to 35 years old.

Inclusion Criteria: - Male or female subjects aged 18 to 35 years inclusive - Subjects with active, moderate acne Exclusion Criteria: - The subject has a secondary acne form (chloracne, drug-induced acne, etc.) (Screening) - The subject has a severity of acne that is not amenable to treatment with CD0271-CD1579 (Screening)

Additional Information

Official title A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
Trial information was received from ClinicalTrials.gov and was last updated in September 2013.
Information provided to ClinicalTrials.gov by Galderma R&D.